Gossamer Bio Inc. Company Profile
NASDAQ: GOSSHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Gossamer Bio at a glance
Gossamer Bio Inc. (NASDAQ: GOSS) is a Biotechnology company in the Healthcare sector headquartered in San Diego, CA. Gossamer Bio is led by Mr. Faheem Hasnain and employs about 161 people. The company's shares have traded publicly since 2019.
At a market capitalization of $60.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001728117, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Gossamer Bio do?
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- Gossamer Bio Inc.
- Ticker
- NASDAQ: GOSS
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Faheem Hasnain
- Employees
- 161
- Headquarters
- 3115 Merryfield Row, San Diego, CA, United States
- Phone
- 858 684 1300
- Website
- gossamerbio.com
- IPO year
- 2019
- Market cap
- $60.43M
- SEC CIK
- 0001728117
Companies similar to Gossamer Bio
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNXTRenovoRx Inc. | 1.33 | -2.92% | $60.02M | vs GOSS |
| MREOMereo BioPharma Group plc ADR | 0.3752 | +6.35% | $59.92M | vs GOSS |
| ELOXEloxx Pharmaceuticals Inc. | 15.18 | +2.02% | $61.27M | vs GOSS |
| KLRSKalaris Therapeutics Inc. | 2.50 | -2.34% | $59.51M | vs GOSS |
| XLOXilio Therapeutics Inc. | 9.01 | 0.00% | $59.29M | vs GOSS |
| IBIOiBio Inc. | 0.92 | -8.91% | $59.16M | vs GOSS |
| PLRXPliant Therapeutics Inc. | 1.00 | +1.01% | $61.92M | vs GOSS |
| BOLDBoundless Bio Inc. | 2.58 | -2.27% | $58.69M | vs GOSS |